Quest Diagnostics Incorporated (DGX) posted a 3% improvement in net revenues of $1.92 billion for the second quarter of 2018 compared to the same period last year. Diagnostic Information Services revenues grew 3.3% in the quarter. Reported net income grew 13.3% to $219 million while diluted EPS rose 14.4% to $1.57 compared to the prior-year period.
Adjusted net income increased 17.3% to $225 million while adjusted diluted EPS saw an improvement of 20.5% to $1.75.
The company’s revenue numbers missed market expectations, but adjusted EPS came in line with analyst estimates. Requisition volume increased 2.5% while revenue per requisition rose 0.2%.
Steve Rusckowski, Chairman, President and CEO, said, “We continue to strengthen our strategic relationship with UnitedHealth Group and are excited to serve as a national in-network lab provider for UnitedHealthcare members beginning January 1, 2019.”
Quest narrowed its full-year 2018 outlook based on its first-half performance. The company now expects revenues to come in between $7.70 billion to $7.74 billion, reflecting revenue growth of 4% to 4.5%. Reported diluted EPS is expected to be between $5.50 and $5.64, while adjusted diluted EPS is expected to be $6.53-6.67 for the full year.
Related: Quest Diagnostics Q1 2018 results and infographic
Related: Quest Diagnostics Inc. Q2 2018 Earnings Call Transcript
Most Popular
V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results
Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew
Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results
Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter
McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings
Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings